bpc-157 fda compounding category Peptide Review 2026: What This Big Shift Means HIMS jumps more than 7%

HIMS jumps more than 7% after an FDA panel recommends adding BPC 157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer New FDA peptide advisers could benefit from their own rulings STAT BPC 157 vs TB 500: Research Compared Dosage Peptide Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand Health Law Alliance Peptides in the Limelight: US FDA May Ease Restrictions on Several Peptides The Dermatology Digest A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring!

SKU: 9948999733 · From jacksfamilyfund.org